Zavicefta, the next-generation antibiotic, is progressing towards reimbursement listing.

According to the industry, Pfizer Pharmaceutical Korea is currently in the final round of discussions with the National Health Insurance Service (NHIS) to settle the reimbursement pricing negotiations for its Zavicefta Inj (ceftazidime·avibactam). Zavicefta received approval from the Health Insurance Review and Assessment Service (HIRA)'s Drug Reimbursement Committee in September 2023, and its negotiations began in November.

When negotiations reach a settlement without any delays, it is anticipated that Zavicefta will be able to get listed for reimbursement next month. Until now, apart fro